Search
Enalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalEnalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible. … As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume
Categories: Antihypertensive Agents Indicated for HypertensionMF-300
go.drugbank.com/drugs/DB32060InvestigationalAs a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983] … MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.
Generalised non-convulsive epilepsy
go.drugbank.com/conditions/DBCOND0017597Drugs: ValpromideSynonyms: Petit mal, Petit-mal seizureSparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. … DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseZonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigational[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. … This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, P-glycoprotein inhibitorsDapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. … [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). … It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Categories: Experimental Unapproved Treatments for COVID-19, Cytochrome P-450 SubstratesFencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnFencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … Fencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsIodoform
go.drugbank.com/drugs/DB13813ApprovedInvestigationalVet approvedWithdrawnDue to its antimicrobial properties following topical administration, minimal levels of iodoform may be found in disinfectants and it is more primarily used for veterinary purposes. … Iodoform is an organoiodine compound with the formula CHI3 and a tetrahedral molecular geometry.